Cr Pharmaceutical

CR Pharmaceutical, a company within the Pharmaceutical Preparation Manufacturing industry headquartered in HK, has reported its carbon emissions for several years. For the reporting year 2024, the company's total emissions were approximately 722,459,800 kg CO2e, comprising 175,023,130 kg CO2e of Scope 1 emissions and 547,436,670 kg CO2e of Scope 2 emissions. In the preceding year, 2023, total emissions were approximately 725,648,620 kg CO2e, with Scope 1 at 170,536,140 kg CO2e and Scope 2 at 555,112,180 kg CO2e. For 2022, total emissions were approximately 722,459,800 kg CO2e, with Scope 1 at 160,986,950 kg CO2e and Scope 2 at 613,993,650 kg CO2e. Emissions data for Scope 3 is not reported for these years.

CR Pharmaceutical has established significant climate commitments. The company aims to achieve carbon neutrality by 2050, covering both Scope 1 and Scope 2 emissions. Furthermore, as part of its near-term strategy aligned with the 14th Five-Year Plan, CR Pharmaceutical is committed to reducing its carbon dioxide emission intensity by 10% by the end of 2025, compared to the 2020 baseline of 0.3184 tonnes/RMB 10,000. Additionally, it plans to decrease comprehensive energy consumption per RMB 10,000 of added value by 8% by the end of 2025, against a 2020 benchmark of 0.1326 tonnes of standard coal/RMB 10,000.

It is important to note that CR Pharmaceutical's emissions data and climate commitments are inherited from its corporate family. Specifically, this data is cascaded from China Resources Pharmaceutical Group Limited, where CR Pharmaceutical is a current subsidiary and the performance data originates from the same source organization at cascade level 0.